Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.

Kang MiaoXiao-Tong Zhang Hanping Wang Xiao-Yan Si Li Zhang

Published in: Thoracic cancer (2023)

In METex14 skipping NSCLC patients, the efficacy of savolitinib and crizotinib did not show significant difference. In MET amplification patients, savolitinib showed better efficacy than crizotinib.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
advanced non small cell lung cancer
small cell lung cancer
prognostic factors
peritoneal dialysis
tyrosine kinase
patient reported outcomes
patient reported